Interfering with Cytotoxic T lymphocyte (CTLA-4) and ProgrammedDeath-1 (PD-1) reportedly has clinical benefits in several human cancers (Odunsi, 2017), so the characterizing associations between MCM10 and immune checkpoints will potentially enhance OV treatment. Here, MCM10 is linked to cancer.